2024年欧洲肿瘤内科学会（ESMO）年会即将于9月13-17日在西班牙巴塞罗那盛大开幕。作为肿瘤学界的盛会，本次会议广泛覆盖了从基础到临床的前沿研究，为医疗专业人士提供了一个交流最新发现和多学科讨论的学术平台。
ESMO官方网站已提前公布了除LBA（Late-Breaking Abstract）之外的摘要标题。本期【肿瘤资讯】整理了乳腺癌领域的重点研究摘要，包括简短口头报告（MO）和口头报告（O），以期为读者带来最前沿的学术资讯。
优选论文专场——转移性乳腺癌
Proffered Paper session - Breast cancer, metastatic
专场时间：2024年09月13日16:00 - 17:30（本文时间均为西班牙时间，比北京时间晚6个小时）
专场地点：Barcelona Auditorium - Hall 2
本专场有3个LBA摘要待确认（TBC）
摘要号：340O
Ⅱ期ICARUS-BREAST01研究：Patritumab Deruxtecan（HER3-DXd）在 HR+/HER2- 晚期乳腺癌患者中的疗效、安全性和生物标志物分析
Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
讲者：Barbara Pistilli (Villejuif, Cedex, France)
简短口头报告专场——早期乳腺癌
Mini oral session - Breast cancer, early stage
专场时间：2024年09月14日10:15-11:45
专场地点：Barcelona Auditorium - Hall 2
本专场有2个LBA摘要TBC
摘要号：233MO
HR 阳性、HER2 阳性乳腺癌的卵巢功能抑制：HERA 试验的探索性分析
Ovarian Function Suppression in HR-positive, HER2-positive Breast Cancer: An Exploratory Analysis from the HERA Trial
讲者：Sohyun Moon (Seoul, Korea, Republic of)
摘要号：234MO
解释年龄、内分泌治疗持续性与HR阳性早期乳腺癌复发风险之间的关系：一项全国性队列研究
Explaining the Relationships between Age, Endocrine Therapy Persistence and Risk of Recurrence in Hormone-Positive Early Breast Cancer: A Nationwide Cohort Study
讲者：Elise Dumas (Paris, France)
摘要号：235MO
NATALEE研究：瑞波西利+非甾体芳香化酶抑制剂（NSAI）在HR+/HER2- 早期乳腺癌年轻患者中的疗效和安全性
Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
讲者：Sherene Loi (Melbourne, Australia, VIC)
摘要号：236MO
Ⅰ期 TNBC 新辅助化疗后的病理学完全缓解和生存期：一项基于注册研究的分析结果
Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study
讲者：Manon De Graaf (Amsterdam, Netherlands)
摘要号：237MO
在接受新辅助紫杉类药物为基础治疗未经免疫治疗的早期TNBC中，TNBC-DX基因组检测的应用
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
讲者：Miguel Martin Jimenez (Madrid, Spain)
摘要号：238MO
PROMENADE：帕博利珠单抗在早期三阴性ER-low乳腺癌中的真实世界法国队列研究
PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
讲者：Francois Cherifi (Caen, Cedex 5, France)
摘要号：239MO
HER2+ 早期乳腺癌的 TILs 和总生存期：ShortHER 试验的 10 年更新分析
TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
讲者：Maria Vittoria Dieci (Padova, Italy)
简短口头报告专场1——转移性乳腺癌
Mini oral session1- Breast cancer, metastatic
专场时间：2024年09月15日08:00-10:00
专场地点：Barcelona Auditorium - Hall 2
本专场有2个LBA摘要TBC
摘要号：341MO
衰老对晚期乳腺癌遗传和转录景观的影响：AURORA Program（BIG 14-01）亚组分析
Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA Program (BIG 14-01) subanalysis
讲者：Gabriele Zoppoli (Genova, Italy, GE)
摘要号：342MO
628 例携带BRCA1、BRCA2 或 PALB2 致病变异的转移性HR阳性乳腺癌患者的结果：基因组学和靶向治疗测序的真实世界数据分析
Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing
讲者：Gerneiva Parkinson (Stanford, United States of America)
摘要号：343MO
揭示德曲妥珠单抗（T-DXd）的作用机制和耐药性：DAISY 试验的补充生物标志物分析
Unraveling the mechanisms of action and resistance to Trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial
讲者：Maria Fernanda Mosele (Villejuif, France)
摘要号：344MO
ESG401，一种新型Trop2抗体偶联药物（ADC），及其在 HER2 阴性转移性乳腺癌伴脑转移中的疗效证据
ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
讲者：马飞 (中国，北京)
摘要号：345MO
IBI354（抗 HER2 ADC）治疗晚期实体瘤和乳腺癌患者：Ⅰ期研究的结果
IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): results from a phase I study
讲者：Charlotte Lemech (Randwick, Australia)
摘要号：346MO
HER2 驱动的乳腺癌和其他恶性肿瘤中T-DXd相关间质性肺病（ILD）的情况：来自法国大型真实世界研究队列的分析结果
Trastuzumab Deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies
讲者：Anthony Canellas (Paris, Cedex 20, France)
简短口头报告专场2——转移性乳腺癌
Mini oral session2- Breast cancer, metastatic
专场时间：2024年09月16日08:30-10:00
专场地点：Barcelona Auditorium - Hall 2
本专场有1个LBA摘要 TBC
摘要号：347MO
Ivonescimab 联合化疗作为TNBC一线治疗的安全性和有效性
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)
讲者：王晓稼（中国, 杭州）
摘要号：348MO
PM8002/BNT327 联合白蛋白结合型紫杉醇一线治疗局晚期或转移性TNBC的安全性和有效性：一项Ib/II期研究
A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
讲者：吴炅（中国, 上海）
摘要号：349MO
ESG401（一种新型 Trop2靶向ADC）在不同亚型转移性乳腺癌患者中的 Ia/Ib 期研究结果
Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer
讲者：马飞（中国, 北京）
摘要号：320MO
Tibremciclib（BPI-16350）联合氟维司群用于内分泌治疗后进展的 HR+/HER2- 晚期乳腺癌患者：一项随机、多中心、双盲、III 期研究
Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study
讲者：胡夕春（中国, 上海）
摘要号：350MO
在HR+/HER2+转移性乳腺癌中添加CDK4/6抑制剂瑞波西利而豁免化疗 - 随机III期DETECT V试验的第二次中期疗效分析
Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer–second interim efficacy analysis of the randomized Phase III DETECT V trial
讲者：Wolfgang Janni (Ulm, Germany)
优选论文专场——早期乳腺癌
Proffered Paper session - Breast cancer, early stage
专场时间：2024年09月16日10:15 - 11:45
专场地点：Barcelona Auditorium - Hall 2
本专场有3个LBA摘要TBC
摘要号：231O
局部区域低剂量与常规剂量放疗在早期乳腺癌中的比较：HypoG-01 Ⅲ期UNICANCER试验的5年结果
Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial
讲者：Sofia Rivera (Villejuif, Cedex, France)
摘要号：232O
高强度运动干预对复发和生存的影响：OptiTrain乳腺癌试验
Effects of a high-intensity exercise intervention on recurrence and survival: the OptiTrain breast cancer trial
讲者：Helene Rundqvist (Stockholm, Sweden)
https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session
排版编辑：肿瘤资讯-张薪媛
推荐阅读
苏公网安备 32059002004080号
